Previous 10 | Next 10 |
NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that two Company abst...
NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the United States Pate...
BeyondSpring Inc. (BYSI) Q4 2019 Earnings Conference Call April 30, 2020 08:00 AM ET Company Participants Caitlin Kasunich - Senior Vice President, KCSA Strategic Communications Lan Huang - Co-Founder, Chairman & Chief Executive Officer Ramon Mohanlal - Executive Vice Preside...
Image source: The Motley Fool. BeyondSpring Inc. (NASDAQ: BYSI) Q4 2019 Earnings Call Apr 30, 2020 , 9:00 a.m. ET Operator Continue reading
NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed its annual report on F...
BeyondSpring (NASDAQ: BYSI ): Q4 GAAP EPS of -$0.52 misses by $0.12 . More news on: BeyondSpring Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- FDA Submission to Change the Primary Endpoint for Study 106 Phase 3 into an Industry First and Robust Clinical Measure to Evaluate Superiority in CIN - - Initiated NDA Rolling Submission for Plinabulin for CIN in China in Q1 2020 - - On Track to Report Interim Analysis of Study ...
BeyondSpring ( BYSI +4.5% ) announces that the FDA has signed off on changing the primary endpoint of its Phase 3 clinical trial, Study 106 , evaluating lead drug Plinabulin for the prevention of chemo-induced neutropenia (abnormally low levels of a type of white blood cell called neutr...
NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BeyondSpring Inc. (NASDAQ: BYSI) please note that in the fifth paragraph of the release, the correct percentage in the second sentence is 40.9, not 37.5 as previousl...
NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a New York-based global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that,...
News, Short Squeeze, Breakout and More Instantly...
COPT Defense Properties of Beneficial Interest (CDP) is expected to report $0.64 for Q2 2024 Bank of Marin Bancorp (BMRC) is expected to report $0.19 for Q2 2024 Oak Ridge Financial Services Inc (BKOR) is expected to report for Q2 2024 D/B/A Centerspace (CSR) is expected to report $1....
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 12.4% to $0.0886 on volume of 1,366,648,994 shares Ascent Solar Technologies Inc (ASTI) rose 63.4% to $0.2147 on volume of 656,794,712 shares Pineapple Energy Inc. (PEGY) rose 61.4% to $...
FLORHAM PARK, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it hosted a virtua...